GlassScriptPhysician profile
Doug S Kim
NPI 1720087067
$8,911.79
in general payments reported to CMS, 2019-2025
44 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $611 · 2021: $1,488 · 2022: $1,267 · 2023: $1,447 · 2024: $1,561 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,349 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,348.76 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.97 | 2019-2025 | |
| Lilly USA, LLC | $1,042.38 | 2019-2025 | Jardiance, Kisunla, Mounjaro |
| Amgen INC. | $595.25 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.76 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $528.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $484.49 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $422.21 | 2020-2025 | Spravato, Xarelto |
| Phathom Pharmaceuticals, INC. | $379.82 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $362.63 | 2021-2025 | |
| Amarin Pharma, INC. | $345.58 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $325.82 | 2020-2021 | |
| Astellas Pharma US INC | $319.40 | 2019-2023 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $240.71 | 2022-2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $216.82 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $208.68 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doug Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.